Genzyme to Invest $80 Million in Framingham, Mass. Site to Expand Manufacturing Capacity for Fabrazyme®

CAMBRIDGE, Mass.--(BUSINESS WIRE)--
Genzyme,
a Sanofi company (EURONEXT: SAN and NYSE: SNY), announced today that it
is investing $80 million to build a new downstream processing facility
for Fabrazyme® (agalsidase beta). The new plant, which will be located
adjacent to the new Fabrazyme cell culture manufacturing site in
Framingham, Massachusetts, will significantly expand purification
capacity to support anticipated growth in global demand over the coming
years.

said Genzyme President and CEO, David Meeker, M.D.

Downstream processing, a vital step in biologic production, involves the
purification of material harvested from the cell culture manufacturing
process. The final product, which is administered as an intravenous (IV)
infusion, is formulated and fill-finished in a separate facility in
Waterford, Ireland and shipped to multiple distribution centers for
labeling, packaging and shipping around the world.

Fabrazyme is approved for treatment of Fabry disease, an inherited
condition that is characterized by excessive accumulation of the lipid
GL-3 in various organs and tissues, which over time can cause renal,
cardiac and cerebrovascular events. As a result, patients with Fabry
disease typically have a shortened life span, and children must often
cope with significant pain and disability. Fabry disease is an inherited
and life threatening disease linked to the X chromosome which affects
approximately 5,000 patients in the world.

Genzyme has pioneered the development and delivery of transformative
therapies for patients affected by rare and debilitating diseases for
over 30 years. We accomplish our goals through world-class research and
with the compassion and commitment of our employees. With a focus on
rare diseases and multiple sclerosis, we are dedicated to making a
positive impact on the lives of the patients and families we serve. That
goal guides and inspires us every day. Genzyme’s portfolio of
transformative therapies, which are marketed in countries around the
world, represents groundbreaking and life-saving advances in medicine.
As a Sanofi company, Genzyme benefits from the reach and resources of
one of the world’s largest pharmaceutical companies, with a shared
commitment to improving the lives of patients. Learn more at www.genzyme.com.

Genzyme® and Fabrazyme® are registered trademarks of Genzyme
Corporation. All rights reserved.

Sanofi, an integrated global healthcare leader, discovers, develops and
distributes therapeutic solutions focused on patients’ needs. Sanofi has
core strengths in the field of healthcare with seven growth platforms:
diabetes solutions, human vaccines, innovative drugs, consumer
healthcare, emerging markets, animal health and the new Genzyme. Sanofi
is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

GenzymeMedia Contact:David
Murdoch, 508-661-1127David.Murdoch@genzyme.com

Source: Genzyme Corporation